Investigational Drug Information for scyllo-inositol
✉ Email this page to a colleague
What is the drug development status for scyllo-inositol?
scyllo-inositol is an investigational drug.
There have been 4 clinical trials for scyllo-inositol.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Alzheimer Disease, Disease, and Psychomotor Agitation. The leading clinical trial sponsors are OPKO Health, Inc., Transition Therapeutics Ireland Limited, and Transition Therapeutics.
Summary for scyllo-inositol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,186 |
| WIPO Patent Applications | 2,411 |
| Japanese Patent Applications | 285 |
| Clinical Trial Progress | Phase 2 (2012-08-01) |
| Vendors | 124 |
Recent Clinical Trials for scyllo-inositol
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | Elan Pharmaceuticals | Phase 2 |
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | OPKO Health, Inc. | Phase 2 |
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | Transition Therapeutics Ireland Limited | Phase 2 |
Clinical Trial Summary for scyllo-inositol
Top disease conditions for scyllo-inositol
Top clinical trial sponsors for scyllo-inositol
US Patents for scyllo-inositol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
